WILMINGTON, Del., Jan. 17, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC, in its recently announced role to provide logistical communications support for a unique "first of its kind self-referential narrative" called "The Patent '813 Story, Part II, Version 2," announced today that the story features a new "group update" that was communicated through a January 16, 2016 at 8:13 pm EST email from the company to the story's "main cast." The "main cast" includes Dr. Flemming Ornskov, CEO of Shire Plc; James Harrington and David Banchik, Intellectual Property Attorneys at Shire LLC and Shire Development LLC respectively; Tatjana May, formerly of Shire but still included in the cast; Ed Haug and Sandra Kuzmich, attorneys with Frommer, Lawrence & Haug LLP; Joe Lucci and David Farisiou, attorneys with Baker Hostetler LLP; Anne Maxwell and Derek Denhart, attorneys with Cantor Colburn LLP; and Louis Sanfilippo, CEO of LCS Group, LLC and Manager of Lucerne Biosciences, LLC. Journalists Steve Lohr of The New York Times and Ed Silverman of the Wall Street Journal, as well as Kevin Penton and Vin Gurrieri of Law360, were included on the "'group update (plus journalism team) to explain what the company [Lucerne Biosciences, LLC] is doing in its communication systems protocol, as well as to inform you of what to expect in the very short time ahead" (see pp. 807-812 of the most recent version of "The Patent '813 Story, Part II, Version 2," below).
Specifically, yesterday's 8:13 pm EST email, sent at that time to numerically symbolize the '813 Patent that the PTAB invalidated on June 4, 2015 on account of an Inter Partes Review initiated by Shire Development LLC on May 9, 2014, stated that there were multiple objectives for a press release issued by Lucerne Biosciences earlier in the day, titled First of its Kind Self-Referential Narrative "The Patent '813 Story, Part II, Version 2" Calls on The New York Times and Wall Street Journal to Investigate Law360 for its Role in Reporting on the Story - The Public-at-Large Also Invited to Join the Investigation. "One of these objectives," according to the electronic communication which was delivered to the "'cast' plus 'journalism team'" by Lucerne Biosciences Manager Louis Sanfilippo, "was to establish what you could call 'narrative-experiential boundary conditions' by which this real-life story begins a rapidly accelerated phase towards its 'final resolution' in which its 'real-time narrative' becomes inextricably wedded to its 'real-time experience' through a process of 'real-time experiential-representational convergence.' What that jargon boils down to is that there's no 'B.S.' once certain communications systems boundary conditions are satisfied."
The 8:13 pm EST communication also identified potential "third-party communication interference" aimed at suppressing distribution of "The Patent '813 Story, Part II, Version 2" to the public-at-large. For example, the 8:13 pm EST communication states, "The numbers this past week look far more ominous as far as suppression of communication goes….[with a] 33/1 ratio of web crawler hits to release views. That's an even higher degree of 'composite third-party communications suppression' than seen in the first 48 hours of the company's June 13, 2015 patent invalidation press release. To put that in comparative perspective, there has been more 'non generative web crawling' in the approximately one week of collectively distributed time for LB's [Lucerne Biosciences] three recent press releases this past week than there was in the approximately nine months of collectively distributed time across the four press releases above (which include the LB June 13, 2015 PTAB invalidation press release) until the time of June 15, 2015. In other words, there's a highly accelerated effort to 'silence Lucerne's version of the story,' even more now than there was in mid-June 2015 when the company sought to announce the invalidation of its own patent because no one else was reporting on it…." The 8:13 pm EST communication adds, "The numbers for [LCS] Group's two press releases this past week, in the email forwarded below, are even more ominous. LCS Group's two press releases generated a total of 25,250 web crawler hits for a total of 431 press release views, generating a 58/1 ratio of web crawler hits to release views. In this respect, the 'third-party interference tech team' has made known that it seems to have more serious issues with LCS Group commercializing the IP it has licensed from the company than it does with the company's interest in making its 'deception detection technology' freely available to the public-at-large, though surely has serious issues with communications made to support either platform. That's very alarming because it indicates that extent to which there is a high-tech effort to willfully interfere in communications related to business, as well as to the kinds of things important to American taxpayers and the public interest, such as free speech, accountability and the information related to the very institutions that make the world work." The 8:13 pm EST communication also informed the group, "The sourcing of this latest tactical communications interference hasn't yet been identified."
"The Patent '813 Story, Part II, Version 2" is a self-referential narrative that utilizes "recursive, non-projective communications" to resolve itself through its "main real life characters." The methodology involves challenging psychological defense mechanisms subject to fantasy and distortion when there are conflicting communications systems that are mutually incompatible and therefore warrant special communication interventions for resolution. As the 8:13 pm EST communication states, "no matter what happens in the story, it brings its attention back to itself and does so within the boundaries of its 'bounded communication system' until it is finally resolved. In other words, it's a story that doesn't ever go away, always redirecting back to its cast of persons, firms and companies, until it resolves itself through its final resolution." With respect to the story's "final resolution," the 8:13 pm EST communication adds, "That process inevitably will happen very fast once certain threshold boundary conditions are satisfied." A further communication to the "'cast' plus 'journalism team,'" pursuant to the 8:13 pm EST one from January 16, 2016, was made on behalf of Lucerne Biosciences, LLC at 7:07 am EST today to inform them of the planned imminent deployment of this press release (see pp. 812-815 of the most recent version of "The Patent '813 Story, Part II, Version 2," below).
Additional, Related Information
The Patent '813 Story, Part II, Version 2 (updated January 17, 2016 at 7:10 AM EST) at: https://app.box.com/s/5a0sw0jheofdbsvp0wutqn79dm3c6s3p)
First of its Kind Self-Referential Narrative "The Patent '813 Story, Part II, Version 2" Calls on The New York Times and Wall Street Journal to Investigate Law360 for its Role in Reporting on the Story - The Public-at-Large Also Invited to Join the Investigation (January 16, 2016) at: http://www.prnewswire.com/news-releases/first-of-its-kind-self-referential-narrative-the-patent-813-story-part-ii-version-2-calls-on-the-new-york-times-and-wall-street-journal-to-investigate-law360-for-its-role-in-reporting-on-the-story-300205470.html or in PDF at: https://app.box.com/s/swdwgasu3ygiyy23nr24gmd40jfkh30r
Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology (January 15, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-300205005.html or in PDF at: https://app.box.com/s/p45yq0h0gun3scx9b8f10uxcoh7vg5q4
LCS Group Accelerates Commercialization Plan of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 15, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300205009.html or in PDF at: https://app.box.com/s/rhdcafckys0u6tffd7vhnkj30g8k7in3
LCS Group Accelerates Commercialization of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using the '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 13, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300204246.html or in PDF at: https://app.box.com/s/t5urotwwyasr964hcvw9afb6xi2lezuv
Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology (January 11, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-begins-accelerated-multi-party-public-expansion-phase-of-its-counter-intelligence-technology-300202785.html or in PDF at: https://app.box.com/s/wlspsobqpnubruhegqvhfjjrxvfvd6n0
PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate (June 13, 2015) at: http://www.prnewswire.com/news-releases/ptab-invalidates-lucerne-biosciences-813-patent-for-the-treatment-of-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300098752.html or in PDF at: https://app.box.com/s/mtbj1r0kbgzx0b2l7umz1i1booloq6ke
LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder (May 13, 2015) at: http://www.prnewswire.com/news-releases/lcs-group-announces-exclusive-license-from-lucerne-biosciences-to-commercialize-813-patent-and-249-application-through-shires-marketing-of-lisdexamfetamine-dimesylate-for-binge-eating-disorder-300083124.html or in PDF at: https://app.box.com/s/08l7mo81abdiogkm2114n6h25pnyc5gg
Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate (March 6, 2015) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-announces-publication-of-claimed-methods-for-treating-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300046271.html or in PDF at: https://app.box.com/s/ielhzv70bgqoi8xwa41rwi7k459vqzia
LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder (December 26, 2014) at: http://www.prnewswire.com/news-releases/lcs-therapeutics-and-lucerne-biosciences-to-commercialize-813-patent-for-lisdexamfetamine-dimesylate-in-the-treatment-of-binge-eating-disorder-300013986.html or in PDF at: https://app.box.com/s/oxpqqzbt83kri117lpl0p2zmoh68uskf
Louis Sanfilippo, MD
Communications can be made to email@example.com.
SOURCE Lucerne Biosciences, LLC